[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University College, London\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":654},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,113,0,25,[9,41,63,93,127,155,180,211,241,271,301,325,352,383,409,419,445,465,489,513,540,562,588,611,630],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100053784","phase-2-to-establish-whether-dapagliflozin-and-spironolactone-in-patients-with-severe-aortic-stenosis-undergoing-aortic-valve-replacement-result-in-better-left-ventricular-mass-regression-myocardial-health-and-patient-reported-outcomes-100053784",false,"NCT07539259","To Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes","Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis - a Randomised Controlled Trial","RELIEF-AS","Inclusion Criteria:\n\n* Participants ≥ 18 years\n* Left Ventricular Ejection Fraction (LVEF) ≥40%.\n* Diagnosed with severe symptomatic aortic stenosis\\* by a cardiologist or cardiac surgeon.\n\n  o Severity of AS follows international guideline criteria \\[38\\], namely at least one out of: effective orifice area \\[EOA\\] \\\u003C1.0 cm2, indexed EOA of ≤0.6 cm2\u002Fm2, peak velocity ≥4.0 m\u002Fs or mean gradient \\>40 mmHg. \\* including severe low flow low gradient AS\n* Referred for surgical or transcatheter AVR (SAVR or TAVI).\n* Able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Current use or intolerance or hypersensitivity to MRAs or SGLT2-inhibitors.\n* Hyperkalaemia (K\\>4.5 mmol\u002FL)\n* Significant renal impairment (eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic insufficiency\n* Concomitant severe other valve lesion (severe MR, MS or AR)\n* Contraindications to MRAs including:\n\n  * Addison's disease.\n  * Acute porphyrias.\n  * Receiving potassium-sparing diuretics, potassium supplements or strong inhibitors of CYP 3A4 (for example. itraconazole, ketoconazole, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazodone).\n* Contraindications to SGLT2-inhibitors including:\n\n  * Active urinary tract infections.\n  * At risk or with a history of diabetic ketoacidosis\n* Type 1 or Type 2 Diabetes on insulin.\n* Concomitant diagnosis affecting trial participation or life expectancy of less than two years as evaluated by the treating clinician.\n* Contraindications to MRI (e.g. non-conditional cardiac pacemaker, severe claustrophobia, inability to lie flat: participants who do not meet local safety rules for MRI). NB: Conditional pacemakers\u002FICDs, if implanted after the baseline scan, are not an exclusion, depending on local expertise.\n* Ongoing participation in another CTIMP interventional clinical trial (i.e. drug trial), will not be permitted. Participation in any other trial will need to be discussed with the trial investigators.\n* Significant comorbidities that would contraindicate participation, including uncontrolled hypertension, or recent myocardial infarction (within 3 months prior to screening).\n* Pregnancy or breastfeeding, or females of childbearing potential not using an effective method of contraception.\n* Any other medical or psychiatric condition that would interfere with participation or compliance with study procedures as determined by the Principal Investigator (PI).\n\n  * As evidenced by features of decompensated cirrhosis e.g. hepatic encephalopathy, ascites, jaundice or markedly deranged liver blood tests e.g. elevated bilirubin, serum albumin \\\u003C30 or deranged clotting","ALL","18 Years",{"count":21,"type":22},445,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This trial aims to improve the heart health of people with a narrowed aortic valve called aortic stenosis (AS) who then have aortic valve replacement (AVR) by assessing the change in the mass of the left ventricle.\n\nEven after an AVR in many patients the heart is still unable to pump as well and can lead to heart failure.\n\nThis study will assess if medication used in other causes of heart failure can help participants having an AVR recover better. Researchers will compare two drugs, dapagliflozin and spironolactone, that have been shown to help patients with heart failure who do not have AS, to see if taking one or both medicines together will help patients with AS.\n\nThere will be four treatment arms: dapagliflozin, spironolactone, dapagliflozin and spironolactone together, and standard of care. These will be taken as one tablet of each IMP per day for 12 months.\n\nParticipants will have approximately four follow up visits, dependent on the treatment arm - those in an arm with spironolactone will have an extra safety follow up visit.\n\nThese medicines might help patients after AVR by reducing heart muscle thickness and scarring.",[28],"Aortic Stenosis","NOT_YET_RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":22},"2026-12",{"date":37,"type":22},"2030-02-28",{"name":39,"class":40},"University College, London","OTHER",{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100053514","tracking-thoracic-cancer-evolution-through-therapy-rx-evo-100053514","NCT05628376","TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO","Inclusion Criteria:\n\n* Cohort A, B and C :\n\n  * Written Informed consent\n  * Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly.\n  * Agreement to be followed up at a TRACERx EVO site\n\nCohort A:\n\n* Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery\n* Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging necessitating surgery (e.g., diagnosis determined from frozen section in theatre)\n* Primary surgery in keeping with NICE guidelines (lobectomy, either open or thoracoscopic), lung parenchymal-sparing operations (segmentectomy or wedge resection) if a complete resection can be achieved, extensive surgery (bronchoangioplastic surgery, bilobectomy, pneumonectomy) if necessary to obtain clear margins, hilar and mediastinal lymph node sampling or en bloc resection)\n* For participants proceeding with upfront primary surgery (i.e. no neoadjuvant therapy), a minimum tumour diameter of at least 15mm on imaging to allow for tissue sampling of at least two tumour regions; this can either be two fresh tissue samples or one fresh tissue sample plus one representative diagnostic FFPE block (to be requested at a later date according to trial specific procedures)\n* Participants undergoing neoadjuvant treatment must have at least 1 region of fresh frozen or FFPE surgical or diagnostic biopsy tissue.\n* Considered sufficiently fit for upfront standard of care primary surgery or neoadjuvant therapy if indicated\n* Performance status 0 to 2\n\nCohort B:\n\n* Participants ≥18 years of age, with late-stage unresectable stage IIIB and above NSCLC disease (TNM 8th edition) or presenting with stage IV de novo metastatic disease.\n* Sufficient tissue (at least 1 region\u002Fbiopsy), either FFPE or fresh frozen\n* Deemed to be fit for anti-cancer treatment\n* Performance status 0 to 2 Participants who were initially consented into Cohort A who are found to have more advanced disease pre- or immediately post operatively (e.g. locally advanced\u002Finoperable or stage IV disease) could be included in Cohort B.\n\nCohort C:\n\n* Participants ≥18 years of age, with any stage SCLC or pleural mesothelioma.\n* Sufficient tissue (at least 1 region\u002Fbiopsy), either FFPE or fresh frozen\n* Deemed to be fit for anti-cancer treatment\n* Performance status 0 to 2\n\nExclusion Criteria:\n\n* Cohort A, B and C:\n\n  * Any other active or current malignancy and\u002For systemic treatment (excluding hormone therapy) for that malignancy in the last 12 months (i.e., participant must be cancer free for the last 12 months, and if on therapy it can only be hormone therapy).\n\n    * Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer, or for Cohort C, cases of NSCLC that have transformed to SCLC, or for Cohort A another synchronous lung cancer.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated severe co-morbid conditions\n\nCohort A:\n\n* Positive margins, incomplete resection or insufficient nodal sampling\n* Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging, or for participants having neoadjuvant therapy at least one tissue biopsy unable to be obtained prior to neoadjuvant therapy (Fresh Frozen or FFPE).\n* Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B\u002FC:\n\n• Insufficient tissue, i.e., at least one tissue biopsy unable to be obtained (Fresh Frozen or FFPE)",{"count":48,"type":22},600,"OBSERVATIONAL","TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.",[52,53,54],"Lung Cancer, Non-small Cell","Small Cell Lung Cancer","Pleural Mesothelioma","RECRUITING",{"date":32,"type":33},{"date":58,"type":33},"2023-10-20",{"date":60,"type":22},"2034-06",{"name":39,"class":40},1,{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100642128","prostate-mri-analysis-by-radiologists-and-artificial-intelligence---disease-identification-and-guided-management-100642128","NCT07647445","Prostate MRI Analysis by Radiologists and Artificial Intelligence - Disease Identification and Guided Management","A Study Assessing Whether Artificial Intelligence is Non-inferior to Radiologists in the Diagnosis of Clinically Significant Prostate Cancer.","PARADIGM","Inclusion Criteria:\n\n1. Men at least 18 years of age referred with clinical suspicion of prostate cancer\n2. Serum PSA ≤ 20 ng\u002FmL\n3. Fit to undergo all procedures listed in the protocol\n4. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. Prior prostate biopsy\n2. Prior prostate MRI on a previous encounter\\*\n3. Prior treatment for prostate cancer\n4. Contraindication to MRI (e.g. claustrophobia, pacemaker)\n5. Metalwork that would give rise to artefact on MRI (e.g. hip prosthesis, pelvic\u002Fspinal metalwork)\n6. Contraindication to prostate biopsy\n7. Unfit to undergo any procedures listed in protocol\n\n   * An MRI on a previous encounter means a previous prostate MRI which has been seen by a doctor and has been used to inform patient management at the time of the original MRI.","MALE",{"count":73,"type":22},500,[75],"NA","Prostate cancer is the most common male cancer in 112 countries and makes up 7% of global cancer cases, and is the second leading cause of cancer-related deaths in men.\n\nNormally, men with suspected prostate cancer undergo a prostate MRI, and then a Radiologist would review this scan to identify any suspicious areas for cancer within the prostate. Prostate MRI interpretation, however, is an expert skill with a steep learning curve, and internationally, there is a growing shortage of Radiologists.\n\nThe PARADIGM trial aims to assess if AI can perform just as well as Radiologists in interpreting prostate MRI scans to identify prostate cancer. Enrolled participants will undergo a prostate MRI, which is the normal method used for investigating suspected prostate cancer. AI and a Radiologist will both interpret the MRI, without knowledge of each other's interpretation. Once both reports have been made, the Radiologist will be asked to produce a third, combined report.\n\nIf there is a suspicious area in the prostate identified either by AI or the Radiologist, targeted biopsies will be performed. If there are no suspicious areas on the MRI and if you are at low risk of harbouring cancer, which occurs in about 30% of men, then no biopsy will be taken at all.",[78],"Prostate CA",[80,81,82,83,84],"MRI","Prostate","Cancer","AI","Artificial Intelligence","2026-06-29",{"date":87,"type":33},"2026-06-30",{"date":89,"type":22},"2026-10",{"date":91,"type":22},"2029-01",{"name":39,"class":40},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":101,"minAge":19,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100608545","phase-2-a-clinical-trial-of-extended-high-treatment-dose-antibiotics-in-combination-with-methenamine-hippurate-compared-to-the-standard-of-care-either-prophylactic-low-dose-antibiotic-treatment-or-methenamine-hippurate-in-females-with-chronic-urinary-tract-infection-100608545","NCT07202949","A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection","EAT-UP - Extended Antibiotic Treatment in Chronic UTI Patients; a Phase II Safety and Efficacy Trial","EAT-UP","Inclusion Criteria:\n\n1. A diagnosis of chronic UTI, without structural or functional urinary tract abnormality\\*, defined as daily persistent symptoms affecting storage (urinary frequency, urgency or urge incontinence) and urinary tract pain symptoms (including bladder pain, urethral pain, or dysuria), for at least 3 months prior to the screening visit, with previously associated transient symptomatic improvement to antibiotic treatment for UTI, which in the opinion of the delegated clinician is secondary to chronic urinary tract infection.\n2. A fresh urine microscopy examination showing ≥20 white blood cells\u002Fµl of urine at the screening visit.\n3. Female\\*\\* patients.\n4. Aged ≥18 years.\n5. Screening blood result of eGFR ≥45ml\u002Fmin\u002F1.73m2.\n6. Able and willing to attend trial visits and comply with all study procedures for the duration of the trial.\n7. Able and willing to provide informed consent prior to any study related assessments and\u002For procedures.\n\n   * A structural or functional abnormality may include kidney reflux, current or long-term catheter use, renal transplant, diversion surgery, renal stones, grade 2 or above utero-vaginal prolapse or incomplete bladder emptying.\n\n     * For the purposes of this trial, a female will be defined as an individual assigned female at birth who has a female urinary tract.\n\nExclusion Criteria:\n\n1. Inability to take at least one of the following antibiotics: Cefalexin, Nitrofurantoin, or Trimethoprim, at prophylactic and treatment dose according to NICE guidelines, and\u002For the Summary of Product Characteristics (such as hepatic or renal dysfunction), or any other medical contraindications.\n2. Inability to take methenamine hippurate due to medical contraindications.\n3. Current use of immune-modulating drugs for the treatment of chronic illnesses such as rheumatoid arthritis, chronic lung disease, any other autoimmune conditions or cancer.\n4. Current use of Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors\\*.\n5. A current diagnosis of bladder cancer.\n6. A diagnosis of an active sexually transmitted infection or a recent diagnosis of a sexually transmitted infection within the last 3 months of the screening visit.\n7. Previous use of an antibiotic at treatment dose as per NICE guidelines for more than 14 consecutive days for treatment of UTI in the last 3 months prior to the screening visit.\n8. Pregnancy (or planned pregnancy during trial participation) and\u002For breastfeeding.\n9. Women of childbearing potential that are unable\u002Funwilling to use an acceptable method of contraception (as described in section 3.4.1) to avoid pregnancy for the duration of the trial and for 1 week after the last dose of trial medication.\n10. Current participation in another clinical trial of a device, interventional medicinal product, advanced therapy, or surgical procedure; or previous participation within 6 months of the screening visit.\n11. Any medical condition or previous treatment which in the investigator's opinion compromises the potential participant's ability to participate.\n\n    * Patient's must not have taken a Sodium-Glucose Transport Protein 2 (SGLT2) inhibitor within 24 hours before the screening visits to be eligible for the trial.","FEMALE",{"count":103,"type":22},192,[25],"Chronic Urinary Tract Infection (UTI) is a type of UTI where symptoms are constant and occur every day, unlike recurrent UTIs, which come and go with symptom-free breaks in between. Current treatment for chronic UTI within the NHS is based on recommended guidelines for recurrent UTI. The standard approach typically includes one of the following treatments:\n\n* Long-term, prophylactic (low) dose daily antibiotic (where medication is used at low doses to try to prevent symptoms reoccurring).\n* Long-term use of a urinary antiseptic (which helps keep your urine bacteria free), called methenamine hippurate.\n\nThese often do not work for people with chronic UTI, and symptoms can persist. Moreover, standard urine tests may fail to detect infections, making diagnosis and treatment more challenging.\n\nThe EAT-UP trial will investigate whether longer courses of treatment (higher) dose antibiotics combined with methenamine hippurate (a urinary antiseptic) are a more effective treatment at reducing levels of infection and symptoms than standard of care treatments (as described above).",[107],"Chronic Urinary Tract Infection",[109,110,111,112,113,114,115,116,107,117],"Urinary Tract Infection","Antibiotics","Urological Diseases","methenamine hippurate","Cefalexin","Nitrofurantoin","Trimethoprim","Amoxicillin","UTI","2026-06-19",{"date":120,"type":33},"2026-06-23",{"date":122,"type":33},"2026-02-26",{"date":124,"type":22},"2027-11",{"name":39,"class":40},4,{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":62},"100642211","respiratory-observation-using-ultra-sensitive-nanotechnology-100642211","NCT07650539","Respiratory OBservation Using Ultra-Sensitive nanoTechnology","Respiratory Observation Using Ultra-Sensitive Nanotechnology","ROBUST","Inclusion Criteria:\n\n* Have capacity to consent to the study\n* Undergoing surgery or receiving oxygen therapy\n\nExclusion Criteria:\n\n* Inability to wear the monitor as designed",{"count":136,"type":22},148,[75],"The Problem - About one in three patients get even more sick while they are in hospital. This often happens because of chest infections, sepsis (very serious infection), or heart problems. These illnesses can make it hard to breathe. They are even more dangerous when patients already have breathing problems.\n\nNurses and doctors need to spot when someone is getting worse as early as possible, so they can help them. For example, giving medicines quickly for sepsis can save lives. Sometimes it's hard to tell when someone is getting worse. Sometimes it's noticed too late. This can be very dangerous. In 2023, nearly 8,000 people died because their illness wasn't spotted quickly enough.\n\nEven if patients don't die, they might need longer in hospital and more care. This costs the NHS a lot more money. It also means fewer beds for other patients. Finding better ways to spot these problems early is an important goal.\n\nThe Opportunity - Research shows checking patients more often helps spot problems early. Nurses do many routine checks. These include blood pressure, temperature, heart rate and oxygen levels.\n\nNurses also check the breathing rate (the number of breaths per minute). Breathing rate is the best way to tell if someone is getting sicker. But it is also the hardest to measure properly. The machines we have don't do it well. So, nurses stand by the patient and count how fast they are breathing. This takes time and can be wrong if the patient talks or moves. Sometimes, it's not done at all.\n\nThe Need - Breathing rate is very useful. But we don't have good tools to measure it easily. We need something simple and accurate. It should also be comfortable for patients and fit into normal hospital care.\n\nOur New Idea - RespiraFibre - We've made a new device called RespiraFibre. It's a tiny, smart sensor. It attaches to the oxygen masks or tubes that patients already wear. It can tell how the patient is breathing. If something is wrong, it sends a warning to the nurse or doctor.\n\nIn this project, we will:\n\n1. Work with patients to make sure the RespiraFibre is comfortable.\n2. Make sure hospital staff find it easy to use.\n3. Test how accurate it is.\n4. Try it out on real hospital wards.\n5. Get it ready to use in hospitals across the country.\n\nThe Impact - We want to treat patients fast if they get sick. To do this, we need early warnings if things are getting worse. This will lead to better care, fewer deaths, and lower costs for the NHS. Our work with RespiraFibre will help make this happen.",[140],"Respiratory Monitoring",[142,143,144,145,146],"Nanotechnology sensor","Continuous respiratory monitoring","Clinical deterioration detection","Validation study","Feasibility study","2026-06-10",{"date":149,"type":33},"2026-06-16",{"date":151,"type":22},"2026-08",{"date":153,"type":22},"2029-02",{"name":39,"class":40},{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100603342","bespoke-decision-support-for-patients-with-newly-diagnosed-localised-prostate-cancer-100603342","NCT07135271","BeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer","Building and Evaluating a Stratified Prostate Cancer Pathway (BeSpoke): the Impact of BeSpoke Decision Support in Patients With Newly Diagnosed Localised Prostate Cancer - a Single-blind Randomised Controlled Trial With Mixed Method Analysis","BeSpoke","Inclusion Criteria for Patient-Participants:\n\n1. Newly diagnosed localised prostate cancer\n2. Clinically suitable for at least two of the following treatment options:\n\n   1. active surveillance\n   2. focal therapy\n   3. radical prostatectomy\n   4. external beam radiotherapy\n3. Willing and able to provide informed consent\n\nExclusion Criteria for Patient Participants:\n\n1. Unsuitable for active treatment due to very low risk prostate cancer or significant health issues.\n2. Suspicion of metastatic prostate cancer based on clinical or imaging evidence including:\n\n   1. Imaging identified suspicious lesion on bone scan, CT, whole-body MRI or PSMA-PET\u002FCT;\n   2. PSA ≥50 ng\u002FmL.\n3. Not able to provide informed consent.\n4. Insufficient English proficiency for adequate use of BeSpoke Decision Support. (Patients with support from a family member, friend or partner, to overcome lack of English proficiency will be included.)\n5. Enrolled in other localised prostate cancer studies where treatment is assigned rather than chosen by participants, e.g. PART Trial (Partial prostate Ablation vs Radical prostaTectomy)\n\nInclusion criteria for Health Care Professionals:\n\n1. Have seen BeSpoke Decision Support and spoken to patients in the intervention arm.\n2. Willing and able to provide written or electronic informed consent\n\nExclusion criteria for Health Care Professionals\n\n1\\. No experience of BeSpoke Decision Support.",{"count":164,"type":22},346,[75],"The goal of this randomised clinical trial is to assess whether personalised treatment counselling can improve the decision-making experience in patients with a new diagnosis of localised prostate cancer. The main question it aims to answer is:\n\n• Does the Bespoke Decision Support tool reduce decisional conflict in those choosing between treatment options for localised prostate cancer?\n\nResearchers will compare the addition of the Bespoke Decision Support tool to standard treatment counselling versus standard counselling alone.\n\nPatient participants will:\n\n* Receive standard counselling with or without access to the Bespoke Decision Support tool (based on arm of randomisation), prior to making a treatment decision.\n* Answer to questionnaires regarding urinary, sexual and bowel function and decision-making outcomes before and after making a treatment decision and at 3, 6, and 12 months after initiating treatment.\n* Take part in a qualitative interview to discuss their decision-making experience\n\nHealth Care Professional participants will:\n\n• Take part in a qualitative interview to discuss their experience in providing decision support in the trial using the Bespoke Decision Support tool.",[168],"Localised Prostate Cancer",[168,170,171,172],"Patient Decision Aid","Shared Decision Making","Randomised Clinical Trial","2026-06-09",{"date":147,"type":33},{"date":176,"type":22},"2026-06",{"date":178,"type":22},"2028-12",{"name":39,"class":40},{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":210},"100370650","phase-1-durvalumab-in-combination-with-s-488210s-488211-vaccine-in-non-muscle-invasive-bladder-cancer-100370650","NCT04106115","DURvalumab in Combination With S-488210\u002FS-488211 vAccine in Non-muscle Invasive Bladder CancEr","A Phase Ib\u002FII Study to Assess the Safety and Activity of DURvalumab (MEDI4736) in Combination With S-488210\u002FS-488211 vAccine in Non-muscle Invasive Bladder CancEr","DURANCE","Inclusion Criteria:\n\n1. Histologically proven high risk non-muscle invasive bladder cancer (NMIBC)\n2. Adequate archival tissue sample available for histological assessment (date sample taken must be within 6 months of planned start of treatment)\n3. Predominant histologic component (\\> 50%) must be urothelial (transitional cell) carcinoma\n4. Bacillus Calmette-Guerin (BCG) unresponsive disease or are intolerant of BCG therapy\n5. Refused or deemed clinically inappropriate for radical cystectomy\n6. ≥18 years of age\n7. Body weight \\>30 kg\n8. World Health Organisation (WHO) performance status 0-1\n9. Must have undergone each of the following procedures within 8 weeks of registration:\n\n   * Complete excision of all papillary disease (T1\u002FTaHG) and demonstration of no muscle invasive disease in the resected specimens (muscle must be present in the tumour sample)\n   * Bladder 'Mapping biopsies' taken\n   * CT of the chest\n   * CT Urogram or MRI of the abdomen and pelvis (if CT is not possible)\n10. Adequate haematological status:\n\n    * Haemoglobin ≥9.0 g\u002FdL\n    * Absolute neutrophil count ≥1.5 x 10\\^9\u002FL (≥150,000 per mm3)\n    * Platelet count ≥100 x 10\\^9\u002FL (≥100,000 per mm3)\n    * International Normalised Ratio (INR) ≤1.5 and Activated Partial Thromoplastin Time (APTT) ≤1.5 x Upper Limit Normal (ULN). NB: This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.\n11. Adequate liver function:\n\n    * Total bilirubin ≤1.5 X ULN (\\\u003C3.0 x ULN for patients with Gilbert's syndrome)\n    * Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≤2.5 x ULN\n12. Adequate renal function: Measured creatinine clearance ≥40 mL\u002Fmin or calculated creatinine clearance ≥40 mL\u002Fmin using Cockcroft-Gault formula.\n13. Life expectancy of ≥6 months\n14. Willing and able to give informed consent (which includes compliance with the requirements and restrictions listed in the patient information sheet (PIS) and in this protocol). NB: Consent must be obtained from the patient\u002Flegal representative prior to performing any protocol-related procedures, including screening evaluations.\n15. Patients of child-bearing potential and male patients with female partners of child-bearing potential must agree to use highly effective contraception methods from date of consent, which must be continued for up to 90 days after last treatment administration.\n16. Female patients must not be pregnant. There should be sufficient evidence of post-menopausal status or a negative serum pregnancy test for pre-menopausal female patients.\n17. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and any other study procedures.\n\nExclusion Criteria:\n\n1. Any history of autoimmune or inflammatory disease including (any patients with a history of an autoimmune condition but without active disease in the last 5 years may be included only after consultation with the CI\u002FTMG):\n\n   * Inflammatory bowel disease (e.g. colitis or Crohn's disease)\n   * Diverticulitis (with the exception of diverticulosis)\n   * Systemic lupus erythematous (SLE)\n   * Sarcoidosis syndrome\n   * Wegener syndrome (granulomatosis with polyangitis, Grave's disease, rheumatoid arthritis, hypophysitis, uveitis, etc.)\n2. Patients with prior allogeneic stem cell or solid organ transplantation\n3. Patients who have had prior treatment with anti- PD-1, PD-L1 or CTLA-4 monoclonal antibody or other novel immune-oncology agent(s)\n4. Active invasive malignancy in the previous 2 years excluding non-melanoma skin cancer\n5. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia) or evidence of active pneumonitis on screening chest CT scan (history of radiation pneumonitis in the radiation field is permitted)\n6. Patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity\n7. QTcF value of \\>470 ms. If prolonged, this should be confirmed by 2 further ECGs each separated by at least 5 minutes.\n8. Patients with the following risk factors for bowel perforation:\n\n   * History of acute diverticulitis or intra-abdominal abcess in the last 3 years\n   * History of mechanical GI obstruction or abdominal carcinomatosis\n9. Any unresolved toxicity CTCAE Grade ≥2 from previous anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. Patients with any irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the CI\u002FTMG\n10. Receipt of last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, embolisation, monoclonal antibodies) within 30 days prior to first dose of trial treatment. NB: If sufficient washout time has not occurred due to the schedule or pharmacokinetic (PK) properties of an agent, a longer washout period will be required, as agreed by the Trial Management Group (TMG) and\u002For Chief Investigator (CI).\n11. Treatment with any experimental drug within 30 days or 5 half-lives (whichever is longer) of the first dose of trial treatment\n12. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\n13. Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial\n14. Received therapeutic oral antibiotics that cannot be discontinued at least 14 days prior to starting treatment or received intravenous (IV) antibiotics within 14 days prior to registration. NB: Patients receiving prophylactic antibiotics (e.g. for prevention of a urinary tract infection or COPD) are eligible\n15. Any psychiatric or other disorder (e.g. brain metastases) that impacts the patients ability to give informed consent or comply with trial treatment and activities\n16. History of leptomeningeal carcinomatosis\n17. Active infection of tuberculosis (TB) (clinically evaluated in accordance with local guidelines, e.g. clinical history, examination and radiographic findings with or without TB testing as clinically indicated)\n18. Patients must not have had systemic corticosteroid therapy (\\>10 mg daily prednisolone equivalent) within 14 days prior to registration or concomitant use of other immunosuppressive medications. NB: The use of inhaled corticosteroids, physiologic replacement doses of glucocorticoids (i.e. for adrenal insufficiency) and mineralocorticoids (e.g. fludrocortisone) are allowed\n19. Administration of a live, attenuated vaccine within 4 weeks prior to planned start of treatment or anticipation that such a live, attenuated vaccine will be required during the study\n20. Evidence of significant uncontrolled concomitant disease that could substantially increase the risk of incurring adverse events (AEs), affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis), uncontrolled hypertension, serious chronic gastrointestinal conditions associated with diarrhoea and uncontrolled major seizure disorder\n21. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of trial treatment. This does not include rigid cystoscopy and biopsies\n22. Significant cardiovascular disease, such as:\n\n    * New York Heart Association cardiac disease (Class II or greater)\n    * Myocardial infarction within 3 months prior to registration\n    * Unstable arrhythmias\n    * Unstable angina\n23. Patients with uncontrolled Type 1 diabetes mellitus. Patients controlled on a stable insulin regimen are eligible\n24. Patients with uncontrolled adrenal insufficiency\n25. Patients with active hepatitis infection (defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen \\[anti-HBc\\] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA\n26. Known active primary immune deficiency, including but not limited to, uncontrolled human immunodeficiency virus (HIV) (detectable viral load) or acquired immunodeficiency syndrome (AIDS)-related illness\n27. Women who are pregnant or breast feeding. Female or male patient of reproductive potential who is not willing to employ highly effective birth control from screening to 90 days after the last dose of trial treatment.\n28. Known allergy or hypersensitivity to any of the investigational products or their excipients\n29. Prior enrolment to, or treatment in a previous durvalumab clinical study, regardless of treatment arm assignment\n30. Patients must not donate blood while participating in this study and for at least 90 days following the last dose of trial treatment",{"count":189,"type":22},52,[191,25],"PHASE1","DURANCE is a two part, phase Ib\u002FII, multi-centre study to assess the safety and activity of S-488210\u002FS-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer (NMIBC).",[194],"Bladder Cancer",[196,197,198,199,200,201,202],"Non-Muscle Invasive Bladder Cancer (NMIBC)","Durvalumab","S-488210\u002FS-488211","Immunotherapy","Vaccine","PD-L1 Inhibitor","BCG unresponsive",{"date":204,"type":33},"2026-06-11",{"date":206,"type":33},"2022-03-25",{"date":208,"type":22},"2032-09-30",{"name":39,"class":40},7,{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":240},"100601593","prism-the-primary-care-individual-social-norms-msk-data-dashboard-a-feasibility-trial-100601593","NCT07112508","PRISM: The PRimary Care Individual Social Norms MSK Data Dashboard: a Feasibility Trial","PRISM: The PRimary Care Individual Social Norms MSK Data Dashboard: a Cluster Randomised Feasibility Trial in Clinician Management of Musculoskeletal Patients.","PRISM","Inclusion and Exclusion Criteria for Sites and Individual FCPs Site Inclusion Criteria\n\n* FCPs (First Contact Physiotherapists) must have regular clinical supervision by a more experienced physiotherapist.\n* Health Care Professionals Council (HCPC) registered Physiotherapists.\n* Provide physiotherapy to NHS patients.\n* Able to send monthly data uploads to the UCL Data Safe Haven to be added to the PRISM dashboard.\n\nPatient Inclusion Criteria\n\n* 18 years of age and above.\n* Registered with a GP practice that is a Participant Identification Centre for this study.\n* Consented to provide outcome measures as part of the trial process.\n\nSite Exclusion Criteria\n\n* No clinical supervision by a more experienced physiotherapist available currently or in practice for the FCPs.\n* Community service physiotherapy.\n* Unable to send data to the UCL Data Safe Haven monthly.\n\nPatient Exclusion Criteria\n\n* Non-musculoskeletal (MSK) problem.\n* Insufficient level of English understanding and expression to allow independent completion of assessment instruments.\n* Lacking capacity or unwilling to consent.\n* Patients who attended FCP but were not treated as they were found to have been an inappropriate referral.",{"count":220,"type":22},60,[75],"Background:\n\n20 million people in UK have musculoskeletal (MSK) aches and pains. They commonly see their GP about this problem, but practices are so busy that it can mean a long wait for appointments. First Contact Practitioner (FCPs) are now working in the GP practices to see patients with MSK problems instead of their GP. A national evaluation has found this to be working well.\n\nFor FCPs working in GP practices there is more clinical risk. The patients have not been previously screened by a doctor to ensure there is no medical cause for their pain. The Chartered Society of Physiotherapists (CSP) has advised that all FCPs be clinicians with the highest level of experience, known as Advanced Practitioners. However the demand for FCPs far outweighs the number of Advanced Practitioners available so physiotherapists being hired have less experience.\n\nEvidence shows that clinicians of different experience levels have different decision-making strategies which may cause unwarranted variation in care. A new method is needed for oversight and support of the FCPs. Clinical supervision is commonly utilised in the NHS and in physiotherapy teams. It is a space to reflect on a clinician's performance and create learning opportunities.\n\nThis research suggests an individual data dashboard, shared only with individuals and their supervisor, that feeds back a clinician's own decision-making data to them, relative to their peers. For example, the participant is \"in the top 20% of MRI requesters\" or \"in the top 20% of those referring to social prescribing\". This type of feedback is known as 'social norms' feedback. It has been proven to be an effective way to change healthcare workers behaviour. The intervention will be called PRISM: Primary Care Individual Social Norms MSK Data Dashboard.\n\nAims To explore the feasibility of a randomised clinical trial comparing the clinical decision-making behaviour of FCP services using the PRISM Dashboard and a usual service with no clinician feedback.\n\nDesign \\& Methods:\n\nThis research is a feasibility trial, a process to assess whether a future full scale clinical trial within the NHS would work. It will take place across 4 different Primary Care commissioning areas to determine the possibility of recruitment, retention, outcome collection and whether people will use the intervention.\n\nPPIE for this research included one primary care PPI rep, one digital interventions PPI rep and 3 Healthwatch PPI reps. Engaging different PPI sources enabled participation from different social , cultural and ethnic backgrounds.\n\nDissemination I will communicate research updates and outputs in conferences, via social media, blogs, newsletters and podcasts. I will use my own network as well as the reach of collaborators in this work, ie. Healthwatch, NHS England\u002FImprovement, The (CSP), the physiotherapy digital network, Keele University and UCL research networks.",[224],"Musculoskeletal Disorders",[226,227,228,229,230,231],"Musculoskeletal","Primary Care","First Contact Physiotherapy","First Contact Practitioner","Digital Health","Behaviour change","2026-06-01",{"date":234,"type":33},"2026-06-04",{"date":236,"type":33},"2026-04-01",{"date":238,"type":22},"2027-11-01",{"name":39,"class":40},2,{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":249,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":253,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":270},"100415129","phase-3-brentuximab-vedotin-in-early-stage-hodgkin-lymphoma-100415129","NCT04685616","Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +\u002F- ISRT With A2VD +\u002F- ISRT in Patients With Previously Untreated Stage IA\u002FIIA Hodgkin Lymphoma","RADAR","Inclusion Criteria:\n\n* Males and females aged 16-69 years (inclusive) (age range is 18-69 in US and EU)\n* Histologically confirmed classical Hodgkin lymphoma\n* Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any level of thoracic vertebra as determined by CT) or B symptoms. Bulky disease at other sites is acceptable. Extranodal disease (single extranodal site (stage I) or contiguous nodal extension (stage II)) is acceptable.\n* ECOG performance status 0-2.\n* No previous treatment for Hodgkin lymphoma\n* Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)\n* Creatinine clearance (measured or calculated \\>40ml\u002Fmin\n* Total bilirubin \\\u003C1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome\n* ALT or AST \\\u003C 2 x upper limit of normal\n* Adequate bone marrow function with neutrophils ≥1.0x10\\^9\u002Fl and platelets ≥100x10\\^9\u002Fl\n* Haemoglobin ≥8g\u002FdL\n* Willing and able to comply with the requirements of the protocol, including contraceptive advice, where applicable\n* Written informed consent\n\nExclusion Criteria:\n\n* Previous treatment for Hodgkin lymphoma, excluding short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days\n* Infradiaphragmatic disease\n* Nodular lymphocyte predominant Hodgkin lymphoma\n* Absence of FDG-avid lesions on baseline PET scan\n* Age 70 years or over or age 15 years or under\n* Other cancer diagnosed with the last 5 years. Patients with completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin are not excluded\n* Recurrent or persistent other cancer within last 5 years irrespective of date of initial diagnosis\n* Pre-existing grade ≥1 sensory or motor neuropathy from any cause\n* History of or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain\n* Symptomatic neurologic disease compromising normal activities of daily living or requiring medications\n* Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive)\n* Any active systemic viral, bacterial or fungal infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first trial drug dose\n* Receiving or recently treated with any other investigational agent (within 4 weeks of trial entry)\n* Pregnant or breastfeeding women\n* Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD\n* Known history of any cardiovascular or respiratory conditions that would preclude anthracycline or bleomycin administration\n* Other significant medical or psychiatric comorbidity that in the opinion of the investigator would make administration of ABVD or A2VD hazardous","16 Years","69 Years",{"count":252,"type":22},1042,[254],"PHASE3","RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia\u002FNew Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry.\n\nEligible patients will be randomised to receive either ABVD or A2VD chemotherapy.\n\nAn interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation.\n\nPatients will be followed up for a minimum of 5 years after treatment.",[257],"Hodgkin Lymphoma",[259,260,261],"PET-response adapted","Stage IA\u002FIIA Hodgkin lymphoma","Brentuximab vedotin","2026-05-29",{"date":264,"type":33},"2026-06-02",{"date":266,"type":33},"2022-04-14",{"date":268,"type":22},"2032-09",{"name":39,"class":40},71,{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":287,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":62},"100490340","electrical-impedance-tomography--selective-stimulation-of-vagus-nerve-100490340","NCT05664854","Electrical Impedance Tomography & Selective Stimulation of Vagus Nerve","Electrical Impedance Tomography Imaging of Functional Anatomy and Selective Stimulation of Fascicles Within the Vagus Nerve","EITsVNS","Inclusion Criteria:\n\n* Age over 18\n* Written informed consent by patient or proxy\n* Clinical diagnosis of disorder affected directly or indirectly or will possibly respond to vagus nerve stimulation\n\nExclusion Criteria:\n\n* Aged 17 and below\n* Unfortunately, it is unlikely that interpreters of all languages will be available in the unit so persons who cannot understand verbal explanation in English and for whom we could not find a suitable consultee would have to be excluded from the study.",{"count":280,"type":22},50,[75],"Electroceuticals is a new field in which the goal is to treat a wide variety of medical diseases with electrical stimulation of autonomic nerves. A prime target for intervention is the cervical vagus nerve as it is easily surgically accessible and supplies many organs in the neck, thorax and abdomen. It would be desirable to stimulate selectively in order to avoid the off-target effects that currently occur. This has not been tried in the past, both because of limitations in available technology but also because, surprisingly, the fascicular organisation of the cervical vagus nerve is almost completely unknown. The aim of this research is to investigate the functional anatomy of fascicles in the cervical vagus nerve of humans. This will include defining innervation to the heart, lungs and recurrent laryngeal and, if possible, the oesophagus, stomach, pancreas, liver and gastrointestinal tract. It will be achieved by defining fascicle somatotopic functional anatomy with spatially-selective vagus nerve stimulation (sVNS) and the new method of fast neural imaging with Electrical Impedance Tomography (EIT). EIT is a novel imaging method in which reconstructed tomographic images of resistance changes related to the opening of ion channels over milliseconds can be produced using rings or arrays of external electrodes. In humans, using a nonpenetrating nerve cuff with sVNS or fast neural EIT, this will be performed for 30 minutes transiently during an operation to insert a vagal nerve stimulator for treatment of epilepsy and deliver images in response to activity such as respiration or the electrocardiogram (ECG).",[284,285,286],"Vagus Nerve Diseases","Epilepsy","Vagus Nerve Autonomic Disorder",[288,289,290,291,292],"Electrical Impedance Tomography","Selective Vagus Nerve Stimulation","Vagus Nerve","Electrophysiology","Vagus Nerve Stimulation","2026-05-26",{"date":295,"type":33},"2026-05-27",{"date":297,"type":33},"2023-12-04",{"date":299,"type":22},"2027-07-31",{"name":39,"class":40},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":311,"conditions":312,"keywords":314,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":324},"100243169","phase-1-carpall-immunotherapy-with-cd19cd22-car-t-cells-for-cd19-and-cd22-acute-lymphoblastic-leukaemia-100243169","NCT02443831","CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia","Immunotherapy With CD19+CD22 CAR Redirected T-cells for High Risk\u002FRelapsed Paediatric CD19+ and CD22+ Acute Lymphoblastic Leukaemia","Inclusion Criteria:\n\n1. Children and young adults (age 24 years or younger) with high risk\u002Frelapsed CD19+ and CD22+ acute lymphoblastic leukaemia with:\n\n   1. Resistant disease (\\>5% blasts) at end of ALLTogether-1 protocol or equivalent induction\n   2. ALL with persisting high level MRD at 2nd time point of frontline national protocol (currently MRD \\>10-4 at week 9 ALLTogether-1 Protocol or equivalent).\n   3. High risk infant ALL (age \\\u003C 6 months at diagnosis with MLL gene rearrangement and either presenting white cell count \\> 300 x 10\\^9\u002FL or poor steroid early response (i.e. circulating blast count \\>1x10\\^9\u002FL following 7 day steroid pre-phase of induction as per national guidelines or equivalent)\n   4. Any patient with t(17,19) TCF3-HLF rearrangement\n   5. High risk 1st relapse (defined as very early (relapse within 18 months of diagnosis) and early relapses (any patient relapsing on therapy or within 6 months of completing treatment) and any relapse with high risk genetics, namely (KMT2A (MLL) rearrangements, low hypodiploidy\u002Fnear haploidy, t(17;19)(q22;p13)\u002FTCF3-HLF, iAMP21 and t(1;19)(q21;p13)\u002FTCF3- PBX1, t(9;22)(34.1 q11.2)\u002FBCR-ABL1\n   6. Any on therapy relapse in patients age 16-24\n   7. Any relapse of infant ALL\n   8. ALL post ≥ 2nd relapse\n   9. Any refractory relapse of ALL (defined as \\> 1% blasts by flow cytometry after a at least 1 cycle of standard chemotherapy)\n   10. ALL with MRD \\>10-4 prior to planned stem cell transplant\n   11. Any relapse of ALL eligible for stem cell transplant but no available HLA matched donor or other contraindication to transplant\n   12. Any relapse of ALL after stem cell transplant as long as planned time of CD19+CD22CAR T cell infusion is \\> 4 months post-transplant\n   13. Early (defined as \\\u003C 6 months post-infusion) loss of B cell aplasia or any CD19+CD22+ relapse following CD19CAR T cell therapy with Tisagenlecleucel\n\n   Note patients with isolated CNS relapse meeting one or more of the criteria above are eligible for the study\n2. Agreement to have a pregnancy test, use adequate contraception (if applicable)\n3. Written informed consent\n\nExclusion Criteria:\n\nExclusion Criteria for registration:\n\n1. Active Hepatitis B, C or HIV infection\n2. Oxygen saturation ≤ 90% on air\n3. Bilirubin \\> 3 x upper limit of normal\n4. Creatinine \\> 3 x upper limit of normal\n5. Women who are pregnant or breastfeeding\n6. Stem Cell Transplant patients only: active significant (overall Grade ≥ II, Seattle criteria) acute GVHD or moderate\u002F severe chronic GVHD (NIH consensus criteria) requiring systemic steroids.\n7. Inability to tolerate leucapheresis\n8. Karnofsky (age ≥ 10 years) or Lansky (age \\\u003C 10) score ≤ 50%\n9. Pre-existing significant neurological disorder (other than CNS involvement of underlying haematological malignancy)\n10. CD19 negative or CD22 negative disease\n\nExclusion criteria for CD19+CD22CAR T-cell infusion:\n\n1. Severe intercurrent infection at the time of scheduled CD19+CD22 CAR T-cell infusion\n2. Requirement for supplementary oxygen or active pulmonary infiltrates at the time of scheduled CD19+CD22 CAR T-cell infusion\n3. Allogeneic transplant recipients with active significant acute GVHD overall grade ≥II or moderate\u002Fsevere chronic GVHD requiring systemic steroids at the time of scheduled CD19+CD22 CAR T-cell infusion. Note: Such patients will be excluded until the patient is GVHD free and off steroids","24 Years",{"count":280,"type":22},[191],"This study aims to evaluate the safety, efficacy and duration of response of CD19+CD22 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in children with high risk, relapsed CD19+ and CD22+ acute lymphoblastic leukaemia",[313],"Acute Lymphoblastic Leukemia",[315],"high risk relapsed CD19+ and CD22+ acute lymphoblastic leukaemia","2026-05-18",{"date":318,"type":33},"2026-05-22",{"date":320,"type":33},"2016-04",{"date":322,"type":22},"2041-12-31",{"name":39,"class":40},3,{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":62},"100634609","a-study-to-evaluate-the-performance-of-confocal-microscopy-to-detect-positive-margins-during-radical-prostatectomy-100634609","NCT07541911","A Study to Evaluate the Performance of Confocal Microscopy to Detect Positive Margins During Radical Prostatectomy","A Study to Evaluate the Performance of En-face Fluorescence Confocal Microscopy (LaserSAFE) for Margin Analysis During Radical Prostatectomy","LaserSAFE","Inclusion Criteria:\n\n* Patients diagnosed with clinically significant operable cT2-T3a N0 M0 PC.\n* Medically fit to undergo RARP.\n* Scheduled for robot-assisted RARP with a recommendation against intrafascial nerve sparing on at least 1 side based on multidisciplinary meetings informed by MRI, biopsy result and clinical factors.\n* Ability to read English sufficiently to understand PIS and able to give informed consent.\n\nExclusion Criteria:\n\n* Patients who received neo-adjuvant ADT.\n* MRI informed very low likelihood for extra prostatic extension in the proximity of NVB (Based on EPE Likert 1 score or tumour away from the posterolateral areas of the prostate)\n* MRI informed high likelihood for extra prostatic extension in the proximity of NVB (based on Likert 5 score or bulging tumour on MRI T2 images)\n* Patients in whom preoperative imaging shows rectal involvement or seminal vesicle invasion in which nerve-sparing is deemed not feasible due to oncological safety concerns.\n* Patients who received previous treatment for prostate cancer: External beam radiotherapy, brachytherapy, focal therapy, chemotherapy.",{"count":334,"type":22},693,[75],"The goal of this study is to find out whether a new method called \"LaserSAFE\" can accurately detect cancer at the edge of the prostate (called a positive margin) during prostate surgery. LaserSAFE uses a special microscope in the operating room to quickly scan the prostate after it has been removed from the body. This information can help surgeons decide whether it is safe to preserve the nerves around the prostate. This is especially important for patients who are not usually considered suitable for nerve-sparing surgery using current methods. The study will also assess how quickly and reliably LaserSAFE provides this information during surgery.\n\nThe main questions it aims to answer are:\n\nCan LaserSAFE accurately detect cancer at the edges of the prostate during surgery? Can LaserSAFE help surgeons safely decide whether to preserve or remove the surrounding nerves?\n\nResearchers will evaluate the use of the LaserSAFE technique during surgery to see if it improves decision-making about nerve preservation compared to standard practice.\n\nParticipants will:\n\nComplete a quality of life questionnaire before surgery Undergo standard prostate surgery, where the surgeon will initially try to preserve the nerves Have their removed prostate analysed during surgery using the LaserSAFE technique Have additional tissue removed if LaserSAFE detects cancer at the edges of the prostate Attend routine follow-up visits as part of standard care Complete quality of life questionnaires at 3 and 12 months after surgery",[338,339],"Prostate Cancer","Prostate Cancer (Adenocarcinoma)",[341,342,343,344],"Confocal microscopy","Prostatectomy","Positive margins","Prostate cancer","2026-05-13",{"date":316,"type":33},{"date":348,"type":33},"2026-04-20",{"date":350,"type":22},"2031-05-20",{"name":39,"class":40},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":363,"conditions":364,"keywords":369,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":62},"100641019","everist-impact-of-image-detected-accessory-pudendal-artery-on-erection-recovery-after-nerve-sparing-prostatectomy-100641019","NCT07597798","EVERiST: Impact of Image Detected Accessory Pudendal Artery on Erection Recovery After Nerve Sparing Prostatectomy","EVERiST: Erectile Function Recovery After Bilateral neuroVascular Bundle Sparing Robot Assisted Radical prostatEctomy in Patients With or Without an Accessory Pudendal aRtery Detected on diagnoSTic Multiparametric MRI: A Feasibility Study","EVERiST","Inclusion Criteria:\n\n* Men diagnosed with cT2-T3a N0 M0 PCa aged between 18 and 79 from all ethnic backgrounds.\n* Patients who underwent a prostate mpMRI before prostate biopsy.\n* Medically fit to undergo RARP.\n* Diagnostic quality prostate biopsies concordant with a diagnostic quality prostate mpMRI adequate to provide a surgical plan.\n* Scheduled for RARP with a recommendation of NVB spare based on multidisciplinary meetings informed by mpMRI, biopsy result and clinical factors.\n* Sexually active men with no to mild ED at baseline based on IIEF-EFD (\\>=24) questionnaire.\n* Preference to preserve erectile function for sexual intercourse.\n* Ability to read English sufficiently to understand PIS and able to give informed consent.\n\nExclusion Criteria:\n\n* Established moderate\u002F severe ED (IIEF-EFD \\\u003C24)\n* Patients who received neo-adjuvant androgen deprivation therapy.\n* Patients with previous surgery for benign prostatic enlargement\n* Patients who received previous treatment for prostate cancer: External beam radiotherapy, brachytherapy, focal therapy, chemotherapy.\n* Previous pelvic or penile fracture\n* Previous surgery for ED\n* Poor quality prostate mpMRI or biparametric MRI (no contrast)\n* Established vascular disease (ischaemic heart disease, cerebrovascular disease, peripheral vascular disease)","79 Years",{"count":362,"type":22},40,"Prostate cancer is the most common cancer amongst men in the United Kingdom, and two common curative treatments are surgery to remove the prostate (radical prostatectomy) or radiotherapy. Both treatments can affect quality of life, mainly because of problems with erections and urinary leakage. Many men feel disappointed or regret their treatment choice because of changes in their sexual function. Surgeons often use a 'nerve-sparing' technique to reduce the risk of erectile dysfunction (ED), but many men still experience erection problems afterwards. A way to improve erectile function recovery after surgery further would be to identify accessory (additional) arteries to the penis. Up to one in three men have an extra artery called the accessory pudendal artery (APA). Preserving this artery during surgery may improve recovery of erections by protecting blood flow and reducing the risk or severity of ED. Until recently, surgeons could only try to see these arteries during the operation, and no study has tested whether they are preserved or whether this makes a difference. This has changed with the advent of imaging. Men already have an advanced MRI scan (called a multiparametric MRI) before prostate cancer treatment. These scans can also show whether an APA is present. In addition, robotic surgery, now the gold standard for radical prostatectomy, allows operations to be video recorded. This allows comparison of what was seen on the scan with what happened during surgery and then monitoring of recovery afterwards. Early research suggests that men with an APA have better erections before surgery. This study will test whether preserving the APA during surgery helps erections recover afterwards.\n\nIn this first phase of the research (Phase 1), a feasibility study will be carried out at University College London Hospital. The study will invite 20-40 men with good sexual function before surgery, who are having robotic prostatectomy with a nerve-sparing approach. Multiparametric MRI scans will be used to identify whether an APA is present and video recordings will be collected to see if the artery was preserved. Participants will complete simple questionnaires on erections and quality of life before and after surgery up to 1 year. To assess whether the artery was preserved, an extra MRI scan will be organised after surgery for those with an APA, as well as penile ultrasound to assess erectile machinery. Ethical approval has already been obtained from the regulatory bodies, and the study is ready to start recruiting participants.\n\nThe results will allow planning of a larger, national study (Phase 2). That study will test whether preserving the APA improves erectile recovery, reduces the severity of ED, and improves quality of life. If confirmed, this research could lead to modification in surgical approach, more personalised counselling before surgery, and reduced long-term need for costly ED treatments within the NHS.",[365,366,367,368],"Radical Prostatectomy","Erectile Dysfunction Following Radical Prostatectomy","Erectile Dysfunction Due to Arterial Insufficiency","Robotic Radical Prostatectomy",[370,371,372,373,374,375],"ED post RARP","Prostate Cancer Survivorship","Erectile dysfunction","Radical prostatectomy","Accessory pudendal artery","APA",{"date":377,"type":33},"2026-05-19",{"date":379,"type":33},"2026-01-15",{"date":381,"type":22},"2028-01-15",{"name":39,"class":40},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":396,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":62},"100638967","potential-for-recovery-of-voluntary-finger-extension-after-stroke-100638967","NCT07592247","Potential for Recovery of Voluntary Finger Extension After Stroke","PROVES","Inclusion Criteria\n\n* Diagnosed with a Stroke \\>6 months previously\n* Medical Research Council (MRC) grade 0 or 1 in long finger extensors.\n\nExclusion Criteria\n\n* Presence of spasticity in any wrist\u002Ffinger flexors (including lumbricals) \\>2 on Modified Ashworth Scale\n* Unable to get hand flat on table top\n* Botulinum toxin to long finger or wrist flexors \\\u003C 24 weeks prior to pre-treatment assessment (i.e. effects should have worn off).",{"count":391,"type":22},100,[75],"Stroke patients with absent voluntary finger extension (VFE) 6-months after stroke are not expected to recover hand function. However, experience from the Queen Square Upper Limb neurorehabilitation service contradicts this view. In this study, we will identify the characteristics of those chronic stroke patients who regain previously absent VFE.\n\nHundred chronic stroke patients will be recruited with absent\u002Fnegligible VFE in an external pilot and feasibility study. Transcranial magnetic stimulation will be used to determine the functional integrity of descending white matter pathways. Corticospinal tract integrity to finger extensor muscles will be based on whether motor-evoked potentials are present (MEP+) or absent (MEP-). Reticulospinal tract activity will be assessed by measuring ipsilateral MEP amplitudes and the Start-React response.\n\nAll patients will then receive 3-months of neuromuscular electrical stimulation plus home exercise, designed to strengthen wrist\u002Ffinger extensors, reduce spasticity and increase corticospinal excitability. The primary outcome measure will be restoration of VFE.\n\nIt is predicted that VFE will be restored in MEP+ but not MEP- patients. MEP- patients will have higher reticulospinal tract activity associated with spasticity. Restoration of VFE will allow patients to engage in evidence-based upper limb training to improve function e.g. constraint induced movement therapy or repetitive task training.",[395],"Stroke",[397,398,399,400,401,402],"Upper limb","Finger extension","Neurophysiological mechanisms","Neurorehabilitation","Motor recovery","functional electrical stimulation",{"date":316,"type":33},{"date":405,"type":22},"2026-09-01",{"date":407,"type":22},"2029-09-01",{"name":39,"class":40},{"id":410,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":23,"phases":413,"briefSummary":26,"conditions":414,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":417,"leadSponsor":418,"locationsCount":4},"100634405","Inclusion Criteria:\n\n* Participants ≥ 18 years\n* LVEF ≥40%.\n* Diagnosed with severe symptomatic AS by the clinical care team.\n\n  o Severe AS defined according to international guideline criteria, namely at least one out of: effective orifice area \\[EOA\\] \\\u003C1.0 cm2, indexed EOA of 0.6 cm2\u002Fm2, peak velocity \\>4.0 m\u002Fs or mean gradient \\>40 mmHg.\n* Referred for surgical or transcatheter AVR (SAVR or TAVI).\n* Able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Current use or intolerance or hypersensitivity to MRAs or SGLT2-inhibitors.\n* Hyperkalaemia (K\\>4.5 mmol\u002FL)\n* Significant renal impairment (eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic insufficiency\n* Contraindications to MRAs including:\n\n  * Addison's disease.\n  * Acute porphyrias.\n  * Receiving potassium-sparing diuretics, potassium supplements or strong inhibitors of CYP 3A4 (for example. itraconazole, ketoconazole, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazodone).\n* Contraindications to SGLT2-inhibitors including:\n\n  * Active urinary tract infections.\n  * At risk of diabetic ketoacidosis (e.g. Type 1 diabetes mellitus)\n* Concomitant diagnosis affecting trial participation or life expectancy of less than two years.\n* History of significant arrhythmias or other cardiac conditions that would interfere with the trial outcomes.\n* Contraindications to MRI (e.g. non-conditional cardiac pacemaker, severe claustrophobia, inability to lie flat: participants who do not meet local safety rules for MRI). NB: Conditional pacemakers\u002FICDs, if implanted after the baseline scan, are not an exclusion, depending on local expertise.\n* Ongoing participation in another interventional clinical trial.\n* Significant comorbidities that would contraindicate participation, including uncontrolled hypertension, or recent myocardial infarction (within 3 months prior to screening).\n* Pregnancy or breastfeeding, or females of childbearing potential not using an effective method of contraception.\n* Any other medical or psychiatric condition that would interfere with participation or compliance with study procedures as determined by the Principal Investigator (PI).",{"count":21,"type":22},[25],[28],{"date":316,"type":33},{"date":35,"type":22},{"date":37,"type":22},{"name":39,"class":40},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":428,"conditions":429,"keywords":432,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":444,"locationsCount":62},"100607757","health-impact-of-non-tuberculous-mycobacteria-pulmonary-disease-ntm-pd-100607757","NCT07192705","Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)","An Observational Cross-sectional Study Exploring Differences in Health Between People With Non-Tuberculous Mycobacteria Pulmonary Disease and People With Bronchiectasis Without NTM Pulmonary Infection.","Inclusion Criteria:\n\n\\- Age: 18 years or older, able to provide informed consent.\n\nNTM-PD Group:\n\n* Participants will be adults diagnosed with confirmed NTM-PD based on the British Thoracic Society (BTS) guidelines.\n* The participant should not be on any antimicrobial therapy (at least two weeks before participation) and should not have previously received or be currently on antimicrobial therapy for NTM-PD.\n\n  \\* BTS guidelines:\n* Clinical (both required):\n* Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution CT scan that shows multifocal bronchiectasis with multiple small nodules.\n* Appropriate exclusion of other diagnoses.\n* Microbiological:\n* A minimum of two positive expectorated sputum culture results of the same NTM species from samples collected on separate days within 12 months before recruitment.\n\nOR\n\n* Positive culture results from at least one bronchial wash or lavage. OR\n* Transbronchial or other lung biopsy with mycobacterial histopathological features (granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathological features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture-positive for NTM.\n\nBronchiectasis Group:\n\n* Diagnosed with bronchiectasis, as confirmed in medical records based on clinical assessment, and radiological findings.\n* Never had a history of positive culture result for NTM pulmonary infection.\n* The latest NTM-negative result must be within the past 12 months from the study's start date or no earlier than 2024.\n\nExclusion Criteria:\n\n\\- Age: Under 18 years of age, or unable to provide informed consent.\n\nNTM-PD Group:\n\n* No confirmation of NTM-PD diagnosis.\n* Diagnosed with a reinfection of NTM-PD.\n* Started antimicrobial therapy for NTM-PD.\n\nBronchiectasis Group:\n\n* No diagnosis of bronchiectasis or diagnosis of bronchiectasis with NTM-PD.\n* Diagnosed with other chronic respiratory diseases considered primary conditions, rather than bronchiectasis.\n* Participants with a history of NTM pulmonary infection.\n* NTM-negative results obtained before 2024.",{"count":427,"type":22},80,"Nontuberculous mycobacteria (NTM) are environmental organisms found in soil and water. The majority do not cause human disease. When they do, this is mostly as a chronic lung infection in people with long-term lung problems such as chronic obstructive pulmonary disease (COPD), bronchiectasis, or cystic fibrosis. The number of people with NTM pulmonary disease (PD) is increasing, and its management can be complex, requiring prolonged treatment with multiple, often toxic, drugs in someone who may already be frail.\n\nNon-drug approaches, such as airway clearance techniques, structured exercise, nutritional support and psychological care are used to help manage bronchiectasis and COPD. However, there is limited evidence about their benefit in people with NTM-PD. Also, it is not clear whether these patients' health needs are different from people with bronchiectasis alone.\n\nThe investigators want to identify the most important symptoms encountered by people with NTM-PD and patient preferences for care. The study also aims to explore whether the need for non-drug measures differs between people with and without NTM-PD who have other underlying lung disease.\n\nThe research will take place at one NHS centre and involve a single assessment of 40 people with NTM-PD not using specific antibiotics to treat their NTM and 40 people with bronchiectasis but no evidence for NTM. Following consent, and mainly using questionnaires, participants will be asked about their physical and mental health, and nutritional status. Exercise capacity, muscle strength and body muscle\u002Ffat composition will also be assessed using simple tests. The total time required will be a maximum of one hour. Recruitment to the study will last around six months.\n\nThe results will help improve understanding of specific needs of people with NTM-PD and guide clinically relevant research in this area.",[430,431],"Non-Tuberculous Mycobacteria Pulmonary Disease","Bronchiectasis",[430,433,434,435,431,436,437,438],"NTM-PD","Non-Tuberculous Mycobacteria Lung Disease","Health Impact of NTM-PD","NTM-LD","Bronchiectasis without NTM-PD","Non-Pharmacological Intervention",{"date":440,"type":33},"2026-05-14",{"date":442,"type":33},"2025-08-14",{"date":232,"type":22},{"name":39,"class":40},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":452,"sex":18,"minAge":453,"maxAge":19,"enrollmentInfo":454,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":462,"leadSponsor":464,"locationsCount":4},"100637956","detection-of-scoliosis-100637956","NCT07581015","Detection of Scoliosis","Early Detection of Adolescent Idiopathic Scoliosis Using Machine Learning on Plantar Pressure Data","Inclusion Criteria:\n\n* Healthy Controls: Adolescents without any spinal condition or significant musculoskeletal issues, and with no prior history of scoliosis, to provide normal plantar pressure data for comparison.\n* Scoliosis Diagnosis: Adolescents diagnosed with adolescent idiopathic scoliosis (AIS) by a healthcare professional (through clinical evaluation and\u002For radiographic assessment) are eligible.\n* Age: Participants must be between the ages of 10 and 18 years at the time of recruitment.\n* Willingness to Participate: Participants and their parent(s)\u002Fguardian(s) must provide informed consent\u002Fassent prior to participation.\n* Ability to Complete Study Procedures: Participants must be able to complete the plantar pressure measurement test, which requires standing on a pressure mat for a few minutes.\n\nExclusion Criteria\n\n* Severe Pain or Discomfort: Participants unable to stand or walk comfortably due to pain or musculoskeletal issues.\n* Non-cooperation: Participants who are unable or unwilling to follow instructions or consent\u002Fassent procedures.\n* Uncontrolled Medical Conditions: Adolescents with uncontrolled conditions (e.g., cardiovascular or endocrine disorders) compromising participation.\n* Recent Foot Injuries or Conditions: Participants with foot injuries or conditions (e.g., wounds, infections) that may interfere with plantar pressure measurement.",true,"10 Years",{"count":73,"type":22},"This study aims to evaluate whether plantar pressure data collected during standing and walking can be used with machine learning to support early detection of scoliosis in young people. Patients with scoliosis and healthy volunteers aged 10-18 will undergo a short assessment using a pressure mat.",[457],"Adolescent Idiopathic Scoliosis (AIS)","2026-05-05",{"date":460,"type":33},"2026-05-12",{"date":176,"type":22},{"date":463,"type":22},"2028-07",{"name":39,"class":40},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":479,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":62},"100624846","phase-1-actinium-in-castrate-resistant-prostate-cancer-after-lutetium-100624846","NCT07414940","ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium","A Multi-site, Prospective, Open-label Phase I\u002FII Trial of Actinium (225Ac) rhPSMA 10.1 to Evaluate Safety and Anti-tumour Activity in Men With Metastatic Castrate-resistant Prostate Cancer (mCRPC) Including Those Who Have Previously Responded to Lutetium-PSMA","ACT-RESoLUTE","Phase I 177Lu-PSMA requirement:\n\nThe first 3 participants treated at each dose level may be 177Lu-PSMA treatment naïve or may have previously received 177Lu-PSMA treatment. Additional participants recruited at any dose level must have received prior 177Lu-PSMA treatment and had a response to therapy, as judged by the treating physician.\n\nPhase II 177Lu-PSMA requirement:\n\nAll participants must have received prior 177Lu-PSMA and had a response to therapy, as judged by the treating physician.\n\nInclusion Criteria:\n\n1. Age ≥ 18 years at time of providing informed consent.\n2. Histologically- or cytologically-confirmed diagnosis of prostate adenocarcinoma, which may include small cell or neuroendocrine features.\n3. Castration-resistant prostate cancer, defined as a rising PSA despite surgical castration or ongoing medical castration, with serum testosterone ≤ 0.5ng\u002FmL or \\\u003C1.7 nmol\u002FL.\n4. Progressive mCRPC with rising PSA level, as defined by PCWG3 criteria, or by radiological progression, and must demonstrate a sequence of rising values above baseline at a minimum of 1-week intervals and PSA \\> 1 ng\u002FmL.\n5. PSMA-avid disease on screening PSMA-PET-CT scan\n6. Prior treatment with at least one second-generation androgen receptor pathway inhibitor (ARPI)\n7. Prior treatment with at least one but no more than two lines of taxane therapy for prostate cancer, or been deemed ineligible or refused taxane therapy on consultation with their treating physician.\n8. At least 4 weeks or 5 half-lives (whichever is longer) elapsed between last anti-cancer treatment administration and the initiation of trial treatment. Anti-cancer treatment includes ARPIs and PARP inhibitors but excludes ADT (e.g. luteinising hormone releasing hormone (LHRH) analogue or gonadotropin-releasing hormone treatment), which should be continued. Prednisone up to 10 mg daily (or equivalent) is also permitted.\n9. Prior treatment with 177Lu-PSMA-targeted radiopharmaceutical therapy (e.g. 177Lu-PSMA-617, 177Lu PSMA-I\\&T) up to a maximum of 6 cycles and with response to therapy as judged by the treating physician.\n\n   Exception: in Phase I, the first 3 participants treated at each dose level may be 177Lu-PSMA naïve Note: last treatment with 177Lu-PSMA must be more than 10 weeks prior to study enrolment.\n10. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.\n11. Estimated life expectancy \\> 12 weeks.\n12. Grade ≤ 1 xerostomia symptoms at time of trial enrolment.\n13. Adequate bone marrow, renal, and hepatic function\n14. Resolution of all previous treatment-related toxicities to CTCAE v5.0 Grade ≤ 1, except for chemotherapy-induced alopecia, Grade 2 peripheral neuropathy, and Grade 2 urinary frequency, which are permitted.\n15. Adequate contraception for participants and their partners.\n16. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.\n2. Active metastatic central nervous system (CNS) disease, including leptomeningeal disease.\n3. Receipt of 177Lu-PSMA treatment within 10 weeks of trial enrolment.\n4. Prior radiotherapeutic treatment for metastatic prostate cancer (e.g. Radium-223) with the exception of 177Lu-PSMA.\n\n   Note: prior radiotherapeutic treatment for other cancers is permitted (e.g. radioactive iodine for thyroid cancer).\n5. Receipt of transfused blood products or erythropoietin stimulating agents within 4 weeks of trial enrolment.\n6. Major surgery within 12 weeks of trial enrolment.\n7. Other current malignancy, or malignancy diagnosed\u002Frelapsed within the past 5 years (other than non melanomatous skin cancer, stage 0 melanoma in situ, or non-muscle invasive bladder cancer that has undergone curative intent therapy).\n8. Sjogren's disease or any other medical conditions that in the judgement of the investigator puts the participant at increased risk of xerostomia.\n9. Single kidney, renal transplant or any nephrotoxic condition or concomitant therapy that in the judgement of the investigator could put the participant at risk of unacceptable renal toxicity during the trial.\n10. Severe urinary incontinence or any other conditions that in the judgement of the investigator would preclude safe disposal of radioactive urine.\n11. Any structural kidney\u002Frenal tract disease that in the judgement of the investigator could affect excretion of the trial agent (e.g. hydronephrosis), unless addressed with intervention (e.g. ureteric stent insertion with normalisation of renal function).\n12. Clinically significant abnormalities on a single 12-lead electrocardiogram (ECG) during screening evaluation.\n13. Concurrent serious conditions that in the judgement of the investigator would pose a safety risk or impair trial participation.\n14. Radiation therapy within 2 weeks before trial enrolment.\n15. Hypersensitivity to the investigational product or any of its constituents.\n16. Current participation in another trial with ongoing receipt of an investigational agent.\n17. Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the trial protocol and follow-up schedule, or that would pose a risk to the participant's safety.",{"count":220,"type":22},[191,25],"Advanced metastatic castration-resistant prostate cancer is a medical condition for which additional effective and tolerable treatments are urgently needed in order to improve patient outcomes and quality of life.\n\nThe goal of this clinical trial is to learn more about Actinium (225Ac) radiohybrid prostate-specific membrane antigen-10.1 (rhPSMA-10.1) injection in men with prostate cancer that has spread and progressed after previous treatments, particularly after Lutetium-PSMA.\n\nActinium (225Ac) rhPSMA-10.1 is an injectable radioactive medication that aims to attach to prostate cancer cells in the body and destroy them using ionising radiation. It is a new medication that has not yet been studied in humans.\n\nParticipants will receive a dose of Actinium (225Ac) rhPSMA-10.1 every 6 weeks, to a maximum of 6 doses. They will be reviewed regularly by the trial researchers to monitor side effects and safety signals. A range of medication doses will be administered so that researchers can find out what doses of the medication are safe for men with prostate cancer. The trial will also aim to determine how effective this medication is for treating advanced prostate cancer.",[477,478,338],"Metastatic Castration-resistant Prostate Cancer","Metastatic Prostate Cancer",[480,481,338],"PSMA","mCRPC",{"date":483,"type":33},"2026-05-08",{"date":485,"type":33},"2026-04-13",{"date":487,"type":22},"2031-12-30",{"name":39,"class":40},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":496,"targetDuration":497,"studyType":49,"phases":4,"briefSummary":498,"conditions":499,"keywords":503,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":62},"100622673","study-of-imaging-and-molecular-biomarkers-in-uncomplicated-rhegmatogenous-retinal-detachment-100622673","NCT07386678","Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment","Cohort-NHS","Inclusion Criteria:\n\n* Adults ≥18 years\n* Uncomplicated primary rhegmatogenous retinal detachment\n* PVD present\n* No PVR-A\u002FB\u002FC\n* Phakic or pseudophakic.\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* Patients lacking capacity\n* Previous vitrectomy\n* Previous cryopexy\n* Aphakia\n* No fundal view\n* Diabetic retinopathy of any severity\n* Retinal detachment secondary to infective causes e.g. acute retinal necrosis, toxoplasmosis scars\n* Retinal detachment secondary to congenital defects e.g. optic disc pit\u002Fcoloboma\n* Exudative retinal detachment\n* Tractional retinal detachment\n* Ongoing involvement in another ocular trial.",{"count":280,"type":22},"3 Months","Disease or general study area: Uncomplicated rhegmatogenous retinal detachment (RRD) and risk of proliferative vittroretinopathy (PVR)\n\nPurpose and nature of the study:\n\n1. Characterise the cytokine profile of vitreous fluid in uncomplicated RRD.\n2. Develop a risk model to predict development of PVR after retinal detachment surgery using imaging and molecular biomarkers.\n3. To develop deep learning\u002Fartificial intelligence (AI) models for PVR detection in retinal detachment.\n\nInclusion criteria:\n\n50 adult ( ≥18 years) patients with uncomplicated rhegmatogenous retinal detachments without PVR.\n\nWhat participating will involve:\n\nPre- and post-operative assessments and intervention will follow standard of care for patients with rhegmatogenous retinal detachments.\n\nAdditional intervention will include non-invasive imaging of anterior chamber flare, vitreous, wide-field retina, macula optical coherence tomography (OCT) and macula OCT-angiography (OCT-A) as well as, seeking participant's consent on collecting their vitreous fluid at time of their surgery for cytokine analysis.",[500,501,502],"Retinal Detachment Rhegmatogenous","Proliferative Vitreoretinopathy","Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment",[504,505],"Cytokines","Imaging",{"date":507,"type":33},"2026-05-06",{"date":509,"type":22},"2026-04-27",{"date":511,"type":22},"2027-01-27",{"name":39,"class":40},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":537,"leadSponsor":539,"locationsCount":62},"100636644","early-phase-1-ai-in-endoscopic-transsphenoidal-surgery-100636644","NCT07568366","AI in Endoscopic Transsphenoidal Surgery","The Application of Artificial Intelligence to Patients Undergoing Endoscopic Transsphenoidal Surgery: a Single-site Prospective Feasibility and Exploratory Study (IDEAL Stage 1 and 2a)","The inclusion criteria will be:\n\n1. Adult patients (above the age of 18 years old)\n2. Undergoing endoscopic transsphenoidal surgery\n3. Able to provide consent\n\nThe exclusion criteria will be:\n\n1. Patients less than 18 years of age\n2. Undergoing transcranial surgery or microscopic transsphenoidal surgery\n3. Unable to provide consent e.g., cannot understand, mental illness, or later withdrawing consent",{"count":521,"type":22},30,[523],"EARLY_PHASE1","This study focuses on bringing artificial intelligence into the operating room to assist with pituitary tumour surgeries performed through the nose. These procedures are technically demanding, and training new surgeons is often inconsistent. To address this, researchers at the National Hospital for Neurology and Neurosurgery are testing AI systems that \"watch\" surgical videos in real-time to identify anatomy, instruments, and the specific phase of the operation.\n\nThe core goal of the prospective trial is to improve education and team coordination without interfering with the surgery itself. The AI displays its analysis on tablets positioned for the surgical residents and nurses, rather than the lead surgeon. This setup allows the team to follow the procedure's progress, key anatomy and anticipate next steps without the surgeon needing to stop and explain. Because hospital internet can be unreliable, the study is prioritizing specialized hardware from NVIDIA that processes data locally. This \"edge computing\" approach ensures the AI is fast and doesn't require a live cloud connection to function.\n\nThis trial will assess the device feasibility (IDEAL Stage 1 study, \\~6 cases), followed by early safety and system technical refinement (IDEAL 2a study, \\~20-30 cases).",[526],"Pituitary Adenoma",[528,529,530,531,532,533],"Artificial intelligence","computer vision","surgical technology","technology translation","pituitary adenoma","endoscopic surgery","2026-04-30",{"date":458,"type":33},{"date":232,"type":22},{"date":538,"type":22},"2029-01-31",{"name":39,"class":40},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":23,"phases":550,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":561},"100533290","cirrhocare--using-smart-phone-technology-to-enhance-care-and-access-to-treatment-for-cirrhosis-100533290","NCT06223893","CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis","CirrhoCare, A Real-world, Randomised Controlled Study, to Determine the Clinical and Cost-effectiveness of CirrhoCare Digital Home Monitoring and Management in Patients With Decompensated Cirrhosis","CirrhoCare","Inclusion criteria:\n\n1. Adults ≥ 18 years and diagnosed with cirrhosis of any aetiology.\n2. Cirrhosis defined by standard clinical criteria, ultrasonographic findings and\u002For histology. Cirrhosis of any aetiology may be included. However, participants with cirrhosis due to autoimmune hepatitis must be on a stable corticosteroid dose for ≥3-month period before study inclusion (to be recorded on concomitant log).\n3. Cirrhosis severity-risk defined by European-Foundation Consortium Liver Failure - Acute Decompensation score (CLIF-C AD score) ≥42 points but ≤65 points at the time of screening.\n4. Hospitalisation for acute decompensation \\[determined as one or more of the following: increasing ascites, variceal haemorrhage, overt hepatic encephalopathy, spontaneous bacterial peritonitis (SBP) or hepatorenal syndrome - acute kidney injury (HRS-AKI)\\].\n5. Participants able to give informed consent.\n\nExclusion criteria:\n\n1. Participants with ACLF grade 2 and above according to the criteria published by Moreau\n2. Participants with CLIF-C AD score ≥ 66, who have a high mortality similar to ACLF ≥2 participants.\n3. Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the West-Haven classification, unable to give consent.\n4. Participants with active hepatocellular carcinoma (HCC) or history of HCC that is in remission for less than six months for uninodular HCC or for less than 12 months for multinodular HCC within Milan criteria.\n5. Participants with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III\u002FIV, COPD GOLD \\>2, chronic kidney disease with serum creatinine \\>2mg\u002FdL or under renal replacement therapy.\n6. Participants with documented refractory ascites on a palliative pathway.\n7. Participants who are active on the transplant waiting list.\n8. Participants with current extra hepatic malignancies including solid tumours and hematologic disorders.\n9. Participants with mental incapacity, significant language barriers, or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study.\n10. Participants with active viral infections, or yet to achieve clear response to anti-viral therapy.\n11. Any disorders likely to impact on study engagement, including severe frailty, severe addiction history (including opioids) with evidence of multiple recent relapses.\n12. Any other reason that the PI considers would make the participant unsuitable to enter CirrhoCare (e.g., participants on an end-of-life palliative care pathway).\n13. Participants enrolled in other interventional trials.",{"count":549,"type":22},214,[75],"The CirrhoCare trial is a multi-centre, open label randomised controlled trial in patients with decompensated cirrhosis. The trial aims to investigate the clinical and cost-effectiveness of CirrhoCare digital home monitoring and management with current standard of care in these patients.",[553],"Decompensated Cirrhosis",{"date":555,"type":33},"2026-05-07",{"date":557,"type":33},"2023-11-24",{"date":559,"type":22},"2027-01-31",{"name":39,"class":40},15,{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":101,"minAge":19,"maxAge":569,"enrollmentInfo":570,"targetDuration":4,"studyType":23,"phases":571,"briefSummary":572,"conditions":573,"keywords":577,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":62},"100634622","impact-of-cmg-vs-vcmg-in-recurrent-stress-incontinence--a-pilot-study-100634622","NCT07542080","Impact of CMG vs VCMG in Recurrent Stress Incontinence- A Pilot Study","Impact of Urodynamic and Video-urodynamic Testing on Surgical Outcomes in Women With Recurrent Urinary Incontinence","Inclusion Criteria:\n\n* competent (able to consent)\n* adult women (over 18 years old)\n* with recurrent stress urinary incontinence\n\nExclusion Criteria:\n\n* women who are pregnant\n* unfit for surgery\n* body mass index (BMI) over 35\n* background of pelvic radiotherapy or relevant neurogenic disease that would put them at risk of neurogenic bladder","100 Years",{"count":521,"type":22},[75],"To asses feasibility of a prospective randomised trial comparing the outcomes of surgery for recurrent urinary incontinence after video-urodynamic(VCMG)and urodynamic(UDS)investigations. One of the greatest challenges for clinicians is the lack of correlation between bothersome urinary symptoms and the underlying urinary tract dysfunction. This has led to the development of several investigations aimed at improving diagnostic accuracy, with UDS and VUDS being the most noteworthy. Despite the heavy reliance on these invasive tests by clinicians, their indications and efficacy remain controversial and supporting literature data is scarce and nonvalidated. The investigators will perform a prospective randomised study of 30 women referred to our tertiary urological services at University College London Hospitals (UCLH) for treatment of recurrent stress urinary incontinence. The women will be investigated with either UDS or VUDS prior to receiving medical and surgical treatment tailored to the identified underlying urinary tract dysfunction. Adult women with symptoms suggestive of recurrent stress urinary incontinence after failed continence surgery will be included. Women who are pregnant, unfit for surgery, have a background of pelvic radiotherapy or relevant neurogenic disease that would put them at risk of neurogenic bladder will be excluded. UDS\u002FVUDS will be performed under the care of Functional, Reconstructive and Adolescent Urology (FFA) Urology Service at UCLH adhering to standardised protocols. Treatment will be provided by FRA Team at UCLH. The primary outcome is assessment of symptoms of urinary incontinence by using validated questionnaires. Results will be correlated with patient characteristics, X-ray exposure, patient experience metrics, outcome and expenses to determine in which sub-populations performing UDS or VUDS has a higher impact on outcomes and when they should be avoided.",[574,575,576],"Stress Incontinence Female","Urodynamic Exam","Urodynamic Stress Incontinence",[578,579,580],"urodynamics","videourodynamics","stress incontinence","2026-04-28",{"date":458,"type":33},{"date":584,"type":33},"2025-10-06",{"date":586,"type":22},"2027-06-06",{"name":39,"class":40},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":610},"100554954","cryoballoonradiofrequencypulsed-field-ablation-of-atrial-fibrillation-versus-medical-treatment-for-heart-100554954","NCT06505798","Cryoballoon\u002FRadiofrequency\u002FPulsed Field Ablation of Atrial Fibrillation Versus Medical Treatment for Heart","CRAAFT-HF","Inclusion criteria:\n\n1. Patients aged ≥18 years.\n2. Patient is willing and able to give informed consent for participation.\n3. Able and willing to comply with all study requirements, including ability to participate in study for 12 months.\n4. Willing to allow their General Practitioner (GP) to be notified of participation in the study.\n5. Patient with one of the following AF categories and at least one episode of AF documented (by any means eg ECG, Holter, Cardiac Implantable Electronic Device (CIED) interrogation or any other means):\n\n   * Paroxysmal AF defined as spontaneous self-terminating AF lasted \\> 6 hours and \\\u003C7 days.\n   * Persistent AF as defined by at least one episode of AF \\>7 days but not \\>3 years (since 1st documentation)\n6. Optimal tolerated medical therapy for HF (including ACE-I (or ARB or ARNi), beta-blocker, SGLT2 inhibitor and mineralocorticoid receptor antagonist (MRA) and cardiac resynchronisation therapy (CRT) where indicated \\& tolerated) for at least 6 weeks (according to the most contemporary European Society of Cardiology (ESC) HF guidelines). Maximal doses of these drugs are not mandated.\n7. New York Heart Association Classification (NYHA) class II to III\n8. LVEF \\\u003C50% (Cardiac imaging report of LVEF\\\u003C50% within 1 year (by echocardiography, cardiac magnetic resonance imaging or nuclear cardiology assessment)) AND after optimisation of medical therapy (see previous definition). Note - a LVEF of \\\u003C50% must be documented by any cardiac imaging performed after optimisation of medical therapy. Documentation of other baseline echocardiographic parameters (eg LA volume, E\u002FE' etc can be obtained from any echocardiogram within 2.5 years). This allows a handheld or echocardiogram focused on LVEF assessment.\n\n   1. For those with LVEF 41-49% and without ongoing atrial fibrillation\u002Fflutter, N-terminal pro B-type natriuretic peptide (NT-proBNP) of ≥300pg\u002FmL is required within 12 months prior to randomisation.\n   2. For those with LVEF 41-49% and with ongoing atrial fibrillation\u002Fflutter, NTproBNP of ≥600pg\u002FmL is required within 12 months prior randomisation.\n   3. For those with LVEF ≤40%, NTproBNP is not required\n\nExclusion criteria:\n\n1. Long standing (\\>3 year) persistent or permanent AF.\n2. Previous atrioventricular (AV) nodal ablation.\n3. Previous pulmonary vein isolation (PVI) or surgical ablation.\n4. Recent (\\\u003C90 days) (type 1 spontaneous) myocardial infarction (type 2 myocardial infarctions are not an exclusion criterion), percutaneous coronary intervention, coronary artery bypass grafting, cardiac resynchronisation therapy or stroke.\n5. Severe aortic or pulmonary valve disease.\n6. Severe primary or secondary mitral valve regurgitation.\n7. Active illness (other than HF) likely to result in death within 2 years.\n8. People who are pregnant or planning to become pregnant during the trial.\n9. People who are breastfeeding.\n10. Known allergy to contrast.\n11. Contraindication for PVI.\n12. Other conditions that may prevent subjects from adhering to the trial protocol, in the opinion of the investigator.\n13. Currently participating in another randomised controlled trial of another drug or medical device.",{"count":596,"type":22},1200,[75],"Atrial fibrillation (AF) is a common heart rhythm disorder that causes an irregular heart beat and is a cause of heart failure (HF). Treatments include drugs to slow the heart rate, anti-arrhythmic drugs or ablation of the heart to help preserve normal rhythm. A number of trials have suggested that ablation may be superior to drug treatment to reduce hospitalisations or prevent early death. However, these studies have been small and the results not applicable to the general population with AF and heart failure in the UK. This international study will compare catheter ablation and optimal medical therapy versus optimal medical therapy alone to see if catheter ablation reduces unplanned heart failure hospitalisations and death rates and improves quality of life.",[600],"Atrial Fibrillation (AF)",[602],"AF",{"date":604,"type":33},"2026-05-04",{"date":606,"type":33},"2024-11-21",{"date":608,"type":22},"2031-12-15",{"name":39,"class":40},24,{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":452,"sex":18,"minAge":618,"maxAge":619,"enrollmentInfo":620,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":627,"completionDateStruct":4,"leadSponsor":629,"locationsCount":362},"100274686","hdclarity-a-multi-site-cerebrospinal-fluid-collection-initiative-to-facilitate-therapeutic-development-for-huntingtons-disease-100274686","NCT02855476","HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease","HDClarity","Inclusion Criteria:\n\n* Age (18-75 years controls, early\u002Flate premanifest HD and incomplete penetrance HD, 21-75 years early\u002Fmoderate\u002Fadvanced manifest HD, ≥11 years juvenile HD)\n* Enroll HD participant\n* Capable of consenting or have a legal representative (parent\u002Fguardian for juveniles)\n* Capable of complying with study procedures\n* All participants other than family and community controls must have had a genetic test for HD\n\nExclusion Criteria:\n\n* Drug trial within 30 days of any sampling visit\n* Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days)\n* Antiplatelet or anticoagulant therapy within 14 days\n* Significant comorbidity\n* Needle phobia, headache, spinal surgery \u002F deformity\n* Clotting or bruising disorder\n* Screening blood test abnormalities \\>10% outside normal range\n* Drug \u002F alcohol abuse\n* Positive urine pregnancy test at any screening or sampling visit for females of childbearing potential\n* Predictable non compliance or unwillingness\n* Serious adverse event related to HDClarity study procedures or any lumbar puncture procedure performed for any reason in the previous 30 days","11 Years","75 Years",{"count":621,"type":22},2500,"HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.",[624],"Huntington's Disease","2026-04-24",{"date":509,"type":33},{"date":628,"type":33},"2017-01-01",{"name":39,"class":40},{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":23,"phases":639,"briefSummary":640,"conditions":641,"keywords":643,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":4},"100635223","middle-meningeal-artery-coagulation-during-burr-hole-drainage-for-chronic-subdural-haematoma-burr-mma-100635223","NCT07549893","Middle Meningeal Artery Coagulation During Burr-Hole Drainage for Chronic Subdural Haematoma (BURR-MMA)","BURR-MMA: A Prospective Pilot Feasibility Study of Intra-operative Middle Meningeal Artery Coagulation During Burr-Hole Surgery for Chronic Subdural Haematoma","BURR-MMA","Inclusion Criteria:\n\n* Age ≥18 years.\n* Chronic or subacute subdural haematoma scheduled for burr-hole evacuation.\n* Treating surgeon considers the CT- and navigation-guided MMA adjunct technically feasible and safe to attempt, recognising that the adjunct may be abandoned intra-operatively according to protocol bail-out criteria.\n* Written informed consent, or consultee declaration under the Mental Capacity Act (MCA), with re-consent if capacity returns.\n\nConsented participants who meet eligibility criteria will be enrolled sequentially until the target sample size of 20-30 participants is reached. No randomisation is used in this feasibility phase.\n\nExclusion Criteria:\n\n* Acute subdural haematoma requiring craniotomy or decompressive surgery.\n* Prior ipsilateral MMA embolisation.\n* Clear contraindication to pre-operative CT\n* Inability to complete Day-90 follow-up.\n* Pregnancy or breastfeeding (due to radiation exposure from CT imaging as part of standard clinical care).\n\nIf CT is non-diagnostic or cannot be performed, participants will continue with standard burr-hole evacuation without the MMA adjunct; this does not constitute a protocol deviation.",{"count":521,"type":22},[75],"Chronic subdural haematoma (cSDH) is a common condition in older adults, usually treated by burr-hole surgery to drain the collection. Even with good surgery, around 1 in 10 patients develop a recurrence and need a second operation. Research shows that the outer lining of the haematoma is fed by small branches of the middle meningeal artery (MMA), and interrupting these branches may lower the risk of recurrence.\n\nThis study looks at whether surgeons can safely and reliably coagulate these small MMA branches at the same time as standard burr-hole drainage, using the routine pre-operative CT scan and surgical navigation already used in everyday practice. Adults (aged 18 years and over) scheduled for burr-hole drainage of a chronic or subacute subdural haematoma will be invited to take part. The procedure, recovery, drain management, and 90-day follow-up will otherwise follow standard NHS care.\n\nNo additional imaging is required for the study, and participants are not exposed to any extra radiation. The main purpose is feasibility and safety, not to prove effectiveness. Findings will inform the design of a future multicentre study.",[642],"Chronic Subdural Hematomas",[644,645,646],"chronic subdural haematoma","middle meningeal artery","burrholes","2026-04-17",{"date":625,"type":33},{"date":650,"type":22},"2026-08-01",{"date":652,"type":22},"2027-12-01",{"name":39,"class":40},""]